An 8-amino-acid cyclic peptide analog of somatostatin with a half-life 30x longer than native somatostatin. FDA-approved for acromegaly, carcinoid syndrome, and neuroendocrine tumors. One of the most clinically important therapeutic peptides in oncology.
Octreotide is a synthetic 8-amino-acid cyclic peptide that mimics the pharmacological effects of the natural hormone somatostatin (SST, 14 amino acids) while having a 30x longer half-life. It was developed by Sandoz (now Novartis) and approved by the FDA in 1988.
Native somatostatin is a powerful inhibitor of growth hormone, insulin, glucagon, and many GI hormones, but its extremely short half-life (3 minutes) made it clinically impractical. Octreotide solved this by incorporating D-amino acids (D-Phe, D-Trp) and a disulfide bridge that resist enzymatic degradation while preserving somatostatin receptor binding.
Octreotide (marketed as Sandostatin) is a synthetic analog of somatostatin — the natural hormone that inhibits the release of growth hormone, insulin, glucagon, and numerous GI hormones. Native somatostatin has a half-life of only 2-3 minutes, making it therapeutically impractical. Octreotide's cyclic structure and D-amino acid substitutions extend the half-life to approximately 90 minutes (subcutaneous) or up to 4 weeks (LAR depot formulation), enabling clinical use.
Octreotide is FDA-approved for three primary indications: treatment of acromegaly (excess GH production, usually from a pituitary adenoma), symptomatic management of carcinoid syndrome and vasoactive intestinal peptide-secreting tumors (VIPomas), and severe diarrhea associated with carcinoid tumors. It is also used off-label for acute GI bleeding (particularly esophageal variceal hemorrhage), hepatorenal syndrome, and various neuroendocrine tumors.
As a somatostatin analog, octreotide belongs to a different therapeutic category from most peptides on this site — it is a well-established FDA-approved medication with decades of clinical use, not an investigational or compounded peptide. It is included in this directory because it exemplifies how peptide engineering (modifying a natural 14-amino-acid hormone) can create a clinically transformative drug.
Octreotide activates somatostatin receptors, particularly SSTR2 (highest affinity) and SSTR5. These are Gi-coupled GPCRs whose activation inhibits adenylyl cyclase, reducing intracellular cAMP. In endocrine cells, reduced cAMP decreases hormone secretion. In tumor cells expressing SSTRs, octreotide inhibits proliferation through cell cycle arrest and may induce apoptosis.
| Pathway | Effect | Significance |
|---|---|---|
| GH suppression | Inhibits pituitary GH release via SSTR2 | Treatment of acromegaly (GH excess) |
| GI hormone inhibition | Reduces secretion of serotonin, VIP, gastrin, and other gut hormones | Controls carcinoid syndrome symptoms (flushing, diarrhea) |
| Antiproliferative | Arrests tumor cell cycle and inhibits angiogenesis | Stabilizes neuroendocrine tumor growth (CLARINET/PROMID trials) |
| Variceal bleeding | Reduces splanchnic blood flow via vasoconstriction | Emergency treatment for acute variceal hemorrhage |
| D-amino acid stability | D-Phe and D-Trp resist protease degradation | 30x longer half-life than native somatostatin (1.5h vs 3 min) |
| Study | Design | Findings | Level |
|---|---|---|---|
| Acromegaly | Extensive RCTs, standard of care | Normalizes GH and IGF-1 in 50-70% of patients. FDA-approved first-line medical therapy. | Level I |
| Carcinoid syndrome | Phase III, PROMID/CLARINET | Controls flushing and diarrhea in >70% of patients. Delays tumor progression. | Level I |
| Neuroendocrine tumors | CLARINET trial, n=204 | Octreotide LAR significantly prolonged progression-free survival vs placebo in GEP-NETs | Level I |
| Variceal bleeding | RCTs | Reduces portal pressure and controls acute hemorrhage. Guideline-recommended. | Level I |
| Acromegaly diagnosis | Octreotide suppression test | Used diagnostically to confirm GH suppressibility and predict surgical outcomes | Level I |
GI side effects: Nausea, diarrhea, abdominal pain, and flatulence are common (20-30% of patients), particularly during the initial weeks of treatment. These effects are related to octreotide's suppression of GI hormone secretion and typically improve over time.
Gallbladder disease: Octreotide slows gallbladder emptying and increases bile lithogenicity, leading to gallstones (cholelithiasis) in 15-30% of patients on long-term therapy. Regular gallbladder monitoring (ultrasound) is recommended for patients on chronic octreotide treatment.
Glucose metabolism: By suppressing both insulin and glucagon secretion, octreotide can cause either hyperglycemia or hypoglycemia depending on the patient's baseline metabolic state. Blood glucose monitoring is recommended, particularly when initiating therapy or adjusting doses.
Cardiac effects: Bradycardia and conduction abnormalities have been reported, particularly with intravenous administration. ECG monitoring may be warranted in patients with pre-existing cardiac disease.
Injection site reactions (LAR): The long-acting depot formulation (Sandostatin LAR) requires deep intramuscular injection and can cause injection site pain, nodules, and rarely, abscess formation.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Sandostatin (SC, 1988), Sandostatin LAR (monthly IM depot). Multiple indications. |
| Biosimilars | Generic octreotide and biosimilar LAR formulations now available |
| WHO | Essential Medicine for acromegaly and neuroendocrine tumors |